Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Source: 
Pharmaceutical Business Review
snippet: 

Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv